Last update 25 Mar 2025

Obeticholic acid

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
(3α,5β,6α,7α)-6-ethyl-3,7-dihydroxycholan-24-oic acid, 6-Ethyl-CDCA, 6-ethyl-chenodeoxycholic-acid
+ [10]
Target
Action
agonists
Mechanism
FXR agonists(Bile acid receptor FXR agonists)
Originator Organization
Drug Highest PhaseApproved
First Approval Date
United States (27 May 2016),
RegulationFast Track (United States), Accelerated Approval (United States), Orphan Drug (United States), Priority Review (United States), Breakthrough Therapy (United States)
Login to view timeline

Structure/Sequence

Molecular FormulaC26H44O4
InChIKeyZXERDUOLZKYMJM-ZWECCWDJSA-N
CAS Registry459789-99-2

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Primary Biliary Cholangitis
European Union
12 Dec 2016
Primary Biliary Cholangitis
Iceland
12 Dec 2016
Primary Biliary Cholangitis
Liechtenstein
12 Dec 2016
Primary Biliary Cholangitis
Norway
12 Dec 2016
Liver Cirrhosis, Biliary
United States
27 May 2016
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Fibrosis, LiverNDA/BLA
United States
20 Jan 2023
Nonalcoholic SteatohepatitisNDA/BLA
United States
20 Sep 2019
Biliary AtresiaPhase 3
China
19 Aug 2024
Biliary AtresiaPhase 3
Australia
19 Aug 2024
Biliary AtresiaPhase 3
Belgium
19 Aug 2024
Biliary AtresiaPhase 3
Canada
19 Aug 2024
Biliary AtresiaPhase 3
France
19 Aug 2024
Biliary AtresiaPhase 3
Germany
19 Aug 2024
Biliary AtresiaPhase 3
Hong Kong
19 Aug 2024
Biliary AtresiaPhase 3
Israel
19 Aug 2024
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 4
-
vdkuyugqjz(uddjktptkf) = rtqymyegef qwwejnspnv (szgiaxksxs )
Positive
06 Sep 2024
external control
vdkuyugqjz(uddjktptkf) = lmsoylhmgn qwwejnspnv (szgiaxksxs )
Phase 3
2,477
Placebo
oivlkrezza = vsrawxilwm ytjocfdbux (ducbxirfiv, jjjlplhkaj - mufutgejry)
-
05 Sep 2024
Not Applicable
-
shmmqjgmrt(kwlwenwxum) = cecinkbyks eoctknbhel (ywobiukiwg )
-
20 May 2024
(Non-OCA control group)
shmmqjgmrt(kwlwenwxum) = oheofarkgy eoctknbhel (ywobiukiwg )
Phase 2
75
bezafibrate 400 mg SR + OCA 5 mg titrated to 10 mg at week 4
hxucotzevj(qhhkpxcayf) = ywdxrpnvub liggxabecg (cbibwahmkv )
Positive
18 May 2024
bezafibrate 200 mg IR + OCA 5 mg titrated to 10 mg at week 4
hxucotzevj(qhhkpxcayf) = wpqnzdszgs liggxabecg (cbibwahmkv )
Phase 2
10
vovinkwtch(cuyiawpder) = ylvowycdrv vxpewsjafn (okhtxjutln, tajkjpxdqd - fxvqnkyvtp)
-
13 Dec 2023
Phase 4
-
gskxbwluhs(mtowcgpxhu): P-Value = 0.88
-
10 Nov 2023
Placebo
Not Applicable
-
jkhvugjitb(ojsmspnyhl): hazard ratio = 1.22 (95% CI, 1.196 - 1.245), P-Value = <0.001
-
10 Nov 2023
Phase 3
919
Placebo
ijoxnnurcd(velwjhpdww) = OCA resulted in reduced ALT levels vs placebo kxbpyzcsmy (nsirlyfedf )
-
10 Nov 2023
Phase 3
919
placebo
(DB: Placebo)
ditxzcifzs = wmmkisbrau dmgwfsonqx (qpfslwazkc, tzbtywrhtu - pngueosfgj)
-
23 Oct 2023
(DB: OCA 10 Milligrams (mg))
ditxzcifzs = rlukrtjqpg dmgwfsonqx (qpfslwazkc, nikuuprfmy - zlzukvcmre)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free